GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Asset Turnover

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Asset Turnover : 0.00 (As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cotinga Pharmaceuticals's Revenue for the three months ended in Jan. 2020 was $0.00 Mil. Cotinga Pharmaceuticals's Total Assets for the quarter that ended in Jan. 2020 was $0.71 Mil. Therefore, Cotinga Pharmaceuticals's Asset Turnover for the quarter that ended in Jan. 2020 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Cotinga Pharmaceuticals's annualized ROE % for the quarter that ended in Jan. 2020 was 58.95%. It is also linked to ROA % through Du Pont Formula. Cotinga Pharmaceuticals's annualized ROA % for the quarter that ended in Jan. 2020 was -231.49%.


Cotinga Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Cotinga Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Asset Turnover Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Asset Turnover falls into.



Cotinga Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cotinga Pharmaceuticals's Asset Turnover for the fiscal year that ended in Apr. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Apr. 2019 )/( (Total Assets (A: Apr. 2018 )+Total Assets (A: Apr. 2019 ))/ count )
=0/( (1.203+0.933)/ 2 )
=0/1.068
=0.00

Cotinga Pharmaceuticals's Asset Turnover for the quarter that ended in Jan. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jan. 2020 )/( (Total Assets (Q: Oct. 2019 )+Total Assets (Q: Jan. 2020 ))/ count )
=0/( (0.715+0.695)/ 2 )
=0/0.705
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cotinga Pharmaceuticals's annulized ROE % for the quarter that ended in Jan. 2020 is

ROE %**(Q: Jan. 2020 )
=Net Income/Total Stockholders Equity
=-1.632/-2.7685
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.632 / 0)*(0 / 0.705)*(0.705/ -2.7685)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.2547
=ROA %*Equity Multiplier
=-231.49 %*-0.2547
=58.95 %

Note: The Net Income data used here is four times the quarterly (Jan. 2020) net income data. The Revenue data used here is four times the quarterly (Jan. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cotinga Pharmaceuticals's annulized ROA % for the quarter that ended in Jan. 2020 is

ROA %(Q: Jan. 2020 )
=Net Income/Total Assets
=-1.632/0.705
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.632 / 0)*(0 / 0.705)
=Net Margin %*Asset Turnover
= %*0
=-231.49 %

Note: The Net Income data used here is four times the quarterly (Jan. 2020) net income data. The Revenue data used here is four times the quarterly (Jan. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cotinga Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019